Marcin Dzienis

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

David A. Palma, Eitan Prisman, Eric Berthelet et al. · JAMA Oncology · 2022 · 102 citations · Full text

Medicine, Oncology, Radiation Oncology +10

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska et al. · The Lancet Oncology · 2021 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes et al. · Journal of Clinical Oncology · 2024 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma

Mehlika Hazar-Rethinam, Lilia Merida de Long, Orla M. Gannon et al. · Molecular Cancer Therapeutics · 2015 · 45 citations · Full text

Medicine, Cancer Biology, Oncology +17